Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety and Tolerability of JLM019 Injection in Patients With Advanced Malignancies

NCT07623850 is registered in ClinicalTrials.gov with Jecho Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07623850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07623850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety and Tolerability of JLM019 Injection in Patients With Advanced Malignancies
Lead sponsor
Jecho Biopharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
January 13, 2026
Completion date
July 1, 2029
Enrollment
115 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor (phase 1), hodgkin lymphoma, non-hodgkin lymphoma